SPRO vs. BNTC

Last updated Jun 4, 2026

SPRO (Spero Therapeutics, Inc.) and BNTC (Benitec Biopharma Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, SPRO returned -27.74%/yr vs -33.23%/yr for BNTC. At a 0.12 correlation, their price movements are largely independent.

Performance

SPRO vs. BNTC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Spero Therapeutics, Inc. (SPRO) and Benitec Biopharma Inc. (BNTC). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, SPRO achieves a 20.17% return, which is significantly higher than BNTC's -22.79% return.

SPRO

• 1D: -1.06%
• 1M: 12.00%
• YTD: 20.17%
• 6M: 22.81%
• 1Y: 6.06%
• 3Y*: 15.44%
• 5Y*: -27.74%
• 10Y*: —

BNTC

• 1D: -1.70%
• 1M: -14.61%
• YTD: -22.79%
• 6M: -17.33%
• 1Y: -33.38%
• 3Y*: 34.95%
• 5Y*: -33.23%
• 10Y*: -29.62%

*Multi-year figures are annualized to reflect compound growth (CAGR)

SPRO vs. BNTC - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
SPRO Spero Therapeutics, Inc.	20.17%	126.21%	-29.93%	-15.03%	-89.19%	-17.43%	101.66%	56.34%	-47.66%	2.17%
BNTC Benitec Biopharma Inc.	-22.79%	6.65%	291.02%	11.76%	-93.51%	-12.67%	-60.78%	-66.00%	-49.27%	5.71%

Correlation

The correlation between SPRO and BNTC is 0.19, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.19
Correlation (3Y) Calculated over the trailing 3-year period	0.15
Correlation (5Y) Calculated over the trailing 5-year period	0.13
Correlation (All Time) Calculated using the full available price history since Nov 3, 2017	0.12

Fundamentals

Market Cap SPRO : $160.39M BNTC : $513.62M
EPS SPRO : $0.39 BNTC : -$1.13
PS Ratio SPRO : 2.93 BNTC : 809.40
PB Ratio SPRO : 3.03 BNTC : 2.80
Total Revenue (TTM) SPRO : $54.77M BNTC : $556.00K
Gross Profit (TTM) SPRO : $54.51M BNTC : $40.00K
EBITDA (TTM) SPRO : $12.49M BNTC : -$55.66M

Return for Risk

SPRO vs. BNTC — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SPRO

SPRO Risk / Return Rank: 44
SPRO Sharpe Ratio Rank: 45
SPRO Sortino Ratio Rank: 43
SPRO Omega Ratio Rank: 42
SPRO Calmar Ratio Rank: 44
SPRO Martin Ratio Rank: 43

BNTC

BNTC Risk / Return Rank: 15
BNTC Sharpe Ratio Rank: 17
BNTC Sortino Ratio Rank: 20
BNTC Omega Ratio Rank: 20
BNTC Calmar Ratio Rank: 8
BNTC Martin Ratio Rank: 10

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SPRO vs. BNTC - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Spero Therapeutics, Inc. (SPRO) and Benitec Biopharma Inc. (BNTC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	SPRO	BNTC	Difference
Sharpe ratio Return per unit of total volatility	0.12	-0.56	+0.67
Sortino ratio Return per unit of downside risk	0.53	-0.48	+1.01
Omega ratio Gain probability vs. loss probability	1.07	0.94	+0.13
Calmar ratio Return relative to maximum drawdown	0.15	-0.85	+1.01
Martin ratio Return relative to average drawdown	0.27	-1.35	+1.62
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

SPRO vs. BNTC - Sharpe Ratio Comparison

The current SPRO Sharpe Ratio is 0.12, which is higher than the BNTC Sharpe Ratio of -0.56. The chart below compares the historical Sharpe Ratios of SPRO and BNTC, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	SPRO	BNTC	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.12	-0.56	+0.67
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.18	-0.33	+0.14
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	-0.22	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.12	-0.30	+0.18

Drawdowns

SPRO vs. BNTC - Drawdown Comparison

The maximum SPRO drawdown since its inception was -97.46%, roughly equal to the maximum BNTC drawdown of -99.91%. Use the drawdown chart below to compare losses from any high point for SPRO and BNTC.

Drawdown Indicators

	SPRO	BNTC	Difference
Max Drawdown Largest peak-to-trough decline	-97.46%	-99.91%	+2.45%
Max Drawdown (1Y) Largest decline over 1 year	-39.80%	-39.25%	-0.55%
Max Drawdown (3Y) Largest decline over 3 years	-68.89%	-68.46%	-0.43%
Max Drawdown (5Y) Largest decline over 5 years	-97.13%	-97.70%	+0.57%
Max Drawdown (10Y) Largest decline over 10 years	—	-99.82%	—
Current Drawdown Current decline from peak	-87.31%	-99.51%	+12.20%
Average Drawdown Average peak-to-trough decline	-62.29%	-87.55%	+25.26%
Ulcer Index Depth and duration of drawdowns from previous peaks	22.79%	24.76%	-1.97%

Volatility

SPRO vs. BNTC - Volatility Comparison

Spero Therapeutics, Inc. (SPRO) has a higher volatility of 17.76% compared to Benitec Biopharma Inc. (BNTC) at 12.09%. This indicates that SPRO's price experiences larger fluctuations and is considered to be riskier than BNTC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	SPRO	BNTC	Difference
Volatility (1M) Calculated over the trailing 1-month period	17.76%	12.09%	+5.67%
Volatility (6M) Calculated over the trailing 6-month period	32.23%	41.17%	-8.94%
Volatility (1Y) Calculated over the trailing 1-year period	52.43%	60.01%	-7.58%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	151.57%	101.68%	+49.89%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	124.80%	132.04%	-7.24%

Dividends

SPRO vs. BNTC - Dividend Comparison

Neither SPRO nor BNTC has paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018
BNTC Benitec Biopharma Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.20%
SPRO Spero Therapeutics, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials

Frequently Asked Questions

Can I hold both SPRO and BNTC in my portfolio?

SPRO and BNTC have a correlation of 0.19, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, SPRO or BNTC?

SPRO has higher volatility (17.76%) compared to BNTC (12.09%). In terms of maximum drawdown, SPRO dropped -97.46% vs BNTC's -99.91%.

Which has better risk-adjusted returns?

SPRO currently has the higher Sharpe Ratio (0.12 vs -0.56), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.